Node Not Found: gynecologic cancerNode Not Found: gynecologic cancerNode Not Found: gynecologic cancerNode Not Found: gynecologic cancerNode Not Found: gynecologic cancerNode Not Found: gynecologic cancer Solid Tumors - The ASCO Post
Advertisement

Your search for solid tumors matches 345 pages

Showing 251 - 300


issues in oncology
solid tumors

Biomarker miR-506 Helps Predict Survival Time in Gastric Cancer Patients

Gastric cancer is typically associated with late-stage diagnosis, as well as high mortality. A study by Li et al in The American Journal of Pathology points to a pivotal role played by the biomarker microRNA (miR)-506 in gastric cancer. Patients whose primary gastric cancer lesions express high...

solid tumors
lung cancer
cns cancers

ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial

An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...

solid tumors
cns cancers

ECC 2015: Advanced Gastrointestinal Neuroendocrine Tumors and Results From the NETTER-1 Trial

Results from a multicenter randomized international trial of an innovative treatment show a marked improvement in the length of time patients with midgut neuroendocrine tumors experience progression-free survival, researchers reported at the 2015 European Cancer Congressin Vienna, Austria, on...

solid tumors

ECC 2015: Use of Aspirin Linked to Improved Survival in Gastrointestinal Cancers

Aspirin improved survival in patients with tumors situated throughout the gastrointestinal tract, results from a large study in the Netherlands showed. This is the first time that survival data from patients with tumors in different gastrointestinal locations have been analyzed at the same time;...

solid tumors
prostate cancer

Decreased Mortality for Men With Unfavorable-Risk Prostate Cancer and Moderate or Severe Comorbidities Treated With Radiotherapy Alone

Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in JAMA. In the letter, ...

solid tumors
hepatobiliary cancer

Study Finds No Recurrence-Free Survival Benefit of Adjuvant Sorafenib in Hepatocellular Carcinoma After Resection or Ablation

In the phase III STORM trial reported in The Lancet Oncology, Bruix et al found no benefit with adjuvant sorafenib (Nexavar) treatment in patients who had undergone resection or ablation for hepatocellular carcinoma. Study Details In this double-blind trial, 1,114 patients from 202 sites in 28...

lung cancer
solid tumors

Statistical Model May Identify Patients Most Likely to Benefit From Mesothelioma Surgery

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma, according to a report published by Leuzzi et al in The Annals of Thoracic Surgery. Malignant pleural mesothelioma is an aggressive...

colorectal cancer
solid tumors

Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer

About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...

solid tumors
issues in oncology

Study Finds Nearly Half of Testicular Cancer Risk Is Inherited

A large European study that combined both population-based and genomic techniques to investigate the heritability of testicular germ cell tumor has found that 48.9% of all the possible factors contributing to risk for the disease are inherited. Rather than being the result of one faulty gene,...

solid tumors
solid tumors

Danish Analysis Indicates Increased Risk of Late Adverse Outcomes in Patients Treated for Relapsed Disseminated Testicular Germ Cell Cancer

In a Danish analysis reported in the Journal of Clinical Oncology, Lauritsen et al found that patients with testicular germ cell cancer who survived after more than one line of treatment for disseminated disease had an increased risk of late toxicity and death resulting from causes other than germ...

solid tumors
gastroesophageal cancer

Long-Term Results of Dutch CROSS Trial Indicate Continued Survival Benefit With Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Initial results of the Dutch phase III CROSS trial showed a significant 5-year overall survival benefit with the addition of neoadjuvant chemoradiotherapy to surgery after a median 45-month follow-up in patients with squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric...

solid tumors
solid tumors

Study Finds Increased Short-Term Risk for Cardiovascular Disease Mortality After Chemotherapy for Testicular Nonseminoma

In a population-based study reported in the Journal of Clinical Oncology, Fung et al found a significantly increased risk of cardiovascular disease mortality during the first year after chemotherapy for testicular nonseminoma. No increased risk of cardiovascular disease mortality after surgery was...

issues in oncology
solid tumors
bladder cancer
issues in oncology

Study Identifies Genetic Mutations That Predict Response to Chemotherapy in Bladder Cancer

Although cisplatin-based neoadjuvant chemotherapy before cystectomy is the standard of care for muscle-invasive bladder cancer, only between 25% and 50% of patients achieve a pathologic response. A study investigating biomarkers that can predict response to chemotherapy in patients with...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

colorectal cancer
solid tumors
pancreatic cancer
supportive care

ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy

The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....

solid tumors

No Benefit of Adding CT to Basic Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism

In a Canadian study reported in The New England Journal of Medicine, Carrier et al found that adding computed tomography (CT) of the abdomen and pelvis to basic screening did not improve detection of occult cancers in patients with a first episode of unprovoked venous thromboembolism. Venous...

solid tumors
issues in oncology

ASCO 2015: Biomarker Analysis Reveals Several Potential Treatment Targets in Subtype of Anal Cancer

Squamous cell anal carcinomas are rare, representing only about 2% of gastrointestinal cancer diagnoses. These cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment. Seeking to...

colorectal cancer
solid tumors
lung cancer

ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...

solid tumors

Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or...

solid tumors

ASCO 2015: Bevacizumab Combination Boosts Survival in Advanced Stomach and Esophageal Cancers

Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these...

colorectal cancer
solid tumors
gynecologic cancer

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

A phase II study identified the first genomic marker—mismatch repair deficiency—to predict clinical benefit of immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab (Keytruda). Among 50 patients with colorectal cancer, 62% of the 25 patients with mismatch...

colorectal cancer
solid tumors
issues in oncology
issues in oncology
issues in oncology

Study Finds Noninvasive Colon Cancer Screening May Be Promising for African Americans

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center, Seidman Cancer Center, and Case Western Reserve University School of Medicine found that a new, noninvasive technology for colon cancer screening is a promising alternative to colonoscopy...

gynecologic cancer
solid tumors
gynecologic cancer
head and neck cancer
issues in oncology

Nine-Valent HPV Vaccine Protects Against 80% of Cervical Cancers

The new nine-valent human papillomavirus (HPV) vaccine (Gardasil 9) can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. Additionally, the new vaccine, which includes seven cancer-causing...

solid tumors

Nilotinib Inferior to Imatinib in First-Line Treatment of Unresectable or Metastatic GIST

In the phase III ENESTg1 trial reported in The Lancet Oncology, Blay et al found that nilotinib (Tasigna) was associated with poorer progression-free survival vs imatinib (Gleevec) as first-line treatment in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Trial...

solid tumors
issues in oncology
sarcoma
issues in oncology

Population-Based Study Finds Patients With Gastrointestinal Tumors at Higher Risk of Other Cancers

Researchers at the University of California (UC) San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers. The results, published by Murphy et al in Cancer,...

breast cancer
gynecologic cancer
prostate cancer
issues in oncology
solid tumors

AACR 2015: New PARP Inhibitor Combination Shows Early Promise for a Wide Range of Cancer Patients

A combination of two molecularly targeted drugs, olaparib (Lynparza) and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2-mutation status, according to data from the...

colorectal cancer
solid tumors
issues in oncology
gastroesophageal cancer

AACR 2015: Long-Term, Regular Aspirin Use Modestly Decreased Cancer Risk

Long-term, regular aspirin use was associated with a modestly reduced overall risk for cancer, driven primarily by a reduction in the risk for colorectal cancers, according to research presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract 876). “Previous...

solid tumors

AACR 2015: Pembrolizumab Safe, With Signs of Clinical Benefit, for Patients With Malignant Pleural Mesothelioma

Pembrolizumab (Keytruda) was safe, tolerable, and yielded robust antitumor responses in patients with malignant pleural mesothelioma, according to data from the phase Ib KEYNOTE-028 clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract CT103)....

palliative care
gynecologic cancer
pancreatic cancer
solid tumors

AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers

Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...

solid tumors

No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma

In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....

issues in oncology
solid tumors

Study Finds Link Between Muscle-Building Supplements and Testicular Cancer

Men who reported taking muscle-building supplements, such as pills and powders with creatine or androstenedione, reported a significantly higher likelihood of having developed testicular cancer than men who did not use such supplements, according to a study by Li et al in the British Journal of...

solid tumors
issues in oncology

Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site

In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....

issues in oncology
solid tumors

Researchers Map Genomic Landscape of Childhood Adrenocortical Tumors for the First Time

In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the genomic landscape of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant...

solid tumors
bladder cancer

Adjuvant Chemotherapy Improves Survival in Patients With Locally Advanced Bladder Cancer

Patients who received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those who underwent surgery alone, according to an analysis presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium, ...

solid tumors
prostate cancer
solid tumors

Men Who Have Had Testicular Cancer May Be More Likely to Develop Prostate Cancer

A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...

issues in oncology
cns cancers
cns cancers
pancreatic cancer
issues in oncology
solid tumors

ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors

A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...

gynecologic cancer
solid tumors

Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Frazier et al used data from U.S. and UK clinical trials to identify a high-risk group of patients with pediatric extracranial germ cell tumors. Study Details The study involved data from seven germ cell tumor trials conducted by the...

issues in oncology
solid tumors

Targeted Next-Generation Sequencing Reveals a High Number of Genomic Mutations in Advanced Malignant Plural Mesothelioma

Next-generation sequencing in malignant pleural mesothelioma tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival, and cell proliferation pathways, according to a study by Lo Iacono et al in the Journal of Thoracic...

solid tumors
bladder cancer

No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer

In the phase III EORTC 30994 trial reported in The Lancet Oncology, Sternberg et al found no overall survival difference between immediate and delayed adjuvant chemotherapy after radical cystectomy in patients with muscle-invasive urothelial carcinoma of the bladder. Immediate treatment was...

solid tumors
solid tumors

Intensified Chemotherapy Based on Tumor Marker Decline May Improve Progression-Free Survival in Patients With Poor-Prognosis Germ Cell Tumors

In the phase III GETUG 13 trial reported in The Lancet Oncology, Fizazi et al found that treatment intensification based on early tumor marker decline resulted in a numeric and borderline statistically significant improvement in progression-free survival in patients with poor-prognosis germ cell...

solid tumors
bladder cancer

Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer

As reported in the Journal of the National Cancer Institute, Mitra et al have identified a novel genomic-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer. Use of the signature could help guide selection of patients for adjuvant therapy...

solid tumors
bladder cancer

RTOG Pooled Analysis Shows Good Long-Term Outcomes After Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer

In a pooled analysis of prospective Radiation Therapy Oncology Group (RTOG) studies reported in the Journal of Clinical Oncology, Mak et al found good long-term outcomes with bladder-preserving combined-modality therapy for muscle-invasive bladder cancer. Study Details The analysis included 468...

solid tumors

Good Long-Term Outcomes With Surveillance for Stage I Nonseminoma Testicular Cancer

In a Danish population-based cohort study reported in Journal of Clinical Oncology, Daugaard and colleagues found that surveillance for stage I nonseminoma testicular cancer after orchiectomy was associated with high cure rate and low treatment burden over long-term follow-up. Study Details The...

solid tumors
gastroesophageal cancer

FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...

solid tumors

First-Line FOLFIRI Improves Time to Treatment Failure and Is Better Tolerated vs ECX in Advanced Gastric Cancer

In a phase III French Intergroup trial reported in the Journal of Clinical Oncology, Guimbaud et al found that FOLFIRI (fluorouracil [5-FU], leucovorin, and irinotecan) significantly prolonged time to treatment failure compared with ECX (epirubicin, cisplatin, and capecitabine) in first-line...

solid tumors

Study Identifies Groups at Risk for Gastrointestinal Stromal Tumors

Researchers at the University of California, San Diego, School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. Of note was the discovery that patients of Asian...

solid tumors

Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer

The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...

solid tumors
solid tumors

Active Surveillance for Clinical Stage I Testicular Cancer Associated With ‘Excellent’ Outcomes

In a retrospective study reported in the Journal of Clinical Oncology, Kollmannsberger et al found that active surveillance for patients with clinical stage I testicular cancer is associated with very good outcomes. Most relapses occurred within 2 years of orchiectomy in patients with nonseminoma...

solid tumors
prostate cancer

Study Suggests That Primary Androgen-Deprivation Therapy Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer

Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...

solid tumors
issues in oncology

Study Defines Four Molecular Subtypes of Gastric Cancer

Investigators of The Cancer Genome Atlas project have developed a molecular classification that divides gastric cancer into four major genomic subtypes, according to a study published in Nature. They include (1) tumors positive for the Epstein-Barr virus (EBV) that display recurrent PIK3CA...

Advertisement



Advertisement